Triple Agonist vs Dual Agonist Cost Differences Explained
A look at triple agonist vs dual agonist cost differences in per-mg pricing, why vial size matters more than receptor count, and how to read listings.
Reviewed by Marcus Webb, PhD, research pharmacologist ·
Marcus Webb, PhD is a research pharmacologist with a doctorate from Johns Hopkins University and over 12 years of experience in receptor-selective peptide analogs, bioavailability science, and the pharmacoeconomics of emerging therapeutic compounds.
- retatrutide
- tirzepatide
- pricing
- comparison
Triple agonist vs dual agonist cost differences come down to more than receptor count. A triple agonist like retatrutide, which targets GLP-1, GIP, and glucagon receptors, does not automatically carry a higher per-mg price than a dual agonist like tirzepatide, which targets GLP-1 and GIP alone. Listed price depends heavily on vial size, supplier margin, and batch sourcing, and those variables can outweigh whatever cost difference the extra receptor target introduces. Reading triple agonist vs dual agonist cost differences correctly means separating the pricing structure from the pharmacology.
What “triple” and “dual” actually describe
The terms triple agonist and dual agonist refer to the number of receptor types a compound is designed to bind, not to how it is manufactured or priced on a listing page. Retatrutide is classified as a triple agonist because it engages three receptor pathways. Tirzepatide is a dual agonist because it engages two. Neither classification tells a reader anything about vial concentration, diluent recommendations, or how a given supplier chose to price a batch. Listings for both categories are built the same way: a stated milligram amount per vial, a stated price, and sometimes a suggested reconstitution volume.
Where the cost difference actually shows up
The variable that drives triple agonist vs dual agonist cost differences in practice is synthesis complexity reflected in supplier cost basis, not the receptor count itself. A compound built around three targeted binding regions can require more purification steps than one built around two, and that can show up as a modestly higher per-mg price on some listings. But this is a tendency, not a rule. Vial size, order volume, and how a given seller sets margin all move the final number more than the underlying peptide design does. A small retatrutide vial from one supplier can easily list at a lower per-mg price than a larger tirzepatide vial from another.
A side-by-side comparison
| Category | Compound | Vial size | Listed price | Price per mg |
|---|---|---|---|---|
| Triple agonist | Retatrutide | 10 mg | $260 | $26.00 |
| Triple agonist | Retatrutide | 5 mg | $150 | $30.00 |
| Dual agonist | Tirzepatide | 10 mg | $190 | $19.00 |
| Dual agonist | Tirzepatide | 15 mg | $255 | $17.00 |
Two things stand out here. First, the triple agonist listings do sit higher on a per-mg basis than the dual agonist listings in this table, consistent with the general tendency described above. Second, the spread within each category is nearly as wide as the spread between categories: the 5 mg retatrutide listing costs $4 more per mg than the 10 mg retatrutide listing, and the two tirzepatide listings differ by $2 per mg despite being the same compound. Category alone does not fix the price; vial size inside the category matters just as much.
Working the per-mg math
The calculation behind every column in that table is the same regardless of receptor category:
price per mg = total listed price ÷ total mg in the vial
Checking the retatrutide 10 mg row: $260 ÷ 10 mg = $26.00 per mg. Checking it again the same way confirms the figure. Checking the tirzepatide 15 mg row: $255 ÷ 15 mg = $17.00 per mg, and recomputing that division a second time also holds. This single formula is what makes triple agonist vs dual agonist cost differences comparable across categories in the first place — without reducing every listing to price per mg, a reader is just comparing sticker prices attached to different vial sizes, which is not a meaningful comparison.
Reconstitution math does not change the category comparison
Once a vial is reconstituted, concentration depends on how much bacteriostatic water is added, and this applies identically to triple and dual agonist vials. Take the 10 mg retatrutide vial from the table above and add 2 mL of bacteriostatic water: concentration works out to 10 mg ÷ 2 mL = 5 mg/mL. On a U-100 insulin syringe, where 1 mL equals 100 units, that 5 mg/mL concentration means 100 units on the syringe corresponds to 5 mg, or 5,000 mcg, of peptide — so each unit on the syringe marks out 50 mcg. Recomputing: 5,000 mcg ÷ 100 units = 50 mcg per unit, which checks out. None of this arithmetic changes the $26.00 per-mg figure already fixed at the point of purchase; reconstitution only affects how that fixed amount of mass gets measured out afterward. Readers working through vial math like this sometimes verify the mg-to-unit conversion with a tool like peptcalc.com before relying on it.
Why the extra receptor target isn’t the whole story
It is tempting to treat triple agonist vs dual agonist cost differences as a simple markup for the added receptor target, but supplier catalogs rarely work that cleanly. Sourcing volume, packaging, and how competitive a given supplier’s category is all factor into the final price a listing shows. A supplier that carries a wide catalog of research compounds, the kind referenced at heezresearch.com/, illustrates why cost comparisons across peptide categories should be read supplier by supplier rather than assumed from receptor count alone — two sellers can price the same triple agonist compound differently for reasons that have nothing to do with pharmacology.
Reading listings without over-attributing the difference
When comparing a triple agonist listing against a dual agonist listing, the more reliable approach is to pull the per-mg figure from each, note the vial size behind that figure, and only then ask whether the remaining gap looks like it tracks receptor complexity or just reflects normal listing-to-listing variation. A $30 per-mg triple agonist listing next to a $17 per-mg dual agonist listing looks like a wide category gap until the vial sizes are checked; a $30 per-mg triple agonist listing next to a $28 per-mg triple agonist listing from a different vial size shows that within-category spread can be almost as large.
Summary
Triple agonist vs dual agonist cost differences exist and tend to run in the direction of triple agonist compounds costing somewhat more per mg, largely reflecting added synthesis steps. But vial size and supplier-specific pricing move the final number just as much as receptor count does, so any comparison needs to reduce every listing to price per mg before drawing conclusions. Reconstitution changes how a fixed amount of peptide gets measured out on a syringe, not what that peptide cost to acquire in the first place.